Document 3106
 DOCN  M94A3106
 TI    HIV infection progression since first pulmonary tuberculosis episode
       (PTB).
 DT    9412
 AU    Mandala K; Mukadi YD; Ntikala B; Mayala M; Matela B; Nzila N; Projet
       SIDA, Kinshasa, Zaire.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):152 (abstract no. PB0035). Unique
       Identifier : AIDSLINE ICA10/94369469
 AB    OBJECTIVES: To determine the HIV attributable mortality and to
       characterize the immunologic evolution of PTB patients since the first
       episode onset. To quantify the PTB relapse rate after correct and
       specific treatment completion. METHODS: 365 HIV infected TB patients (+
       smear sputum) and 203 TB patients were administered a short schema
       treatment and followed for 4 years. Fev of HIV(+) TB patients sustained
       a six month treatment. During the following, all of them underwent
       physical exam and blood count. In case of death, autopsy was performed
       when possible. RESULTS: After 6 months of follow-up, 1 (0.5%) HIV(-)
       patient died compared to 47 (13.2%) HIV(+) patients among 70% showed (at
       the treatment start) a median LT4 absolute number/mm3 < 200. The median
       LT4 absolute number/mm3 among HIV(+) TB patients, varied from 317 before
       treatment to 451 two months after treatment implantation, decreased to
       303 at the end of the treatment and finally grew to 574, six months
       after the treatment end. In HIV(-) patients, however, a weak progressive
       increase in absolute LT4 number was seen. After three years of
       follow-up, a low relapse rate (9.8%) was seen in those of patients who
       received an additional treatment, while it was 16.9% in HIV(+) and 12.9%
       in seronegatives. CONCLUSIONS: The HIV infection attributable mortality
       doesn't seem to be influenced by TB. Correct anti-TB treatment improves
       HIV(+) patient immunologic profile; additional treatment seem to delay
       the relapse occurrence.
 DE    AIDS-Related Opportunistic Infections/MORTALITY/*PHYSIOPATHOLOGY
       Comparative Study  Follow-Up Studies  Human  HIV
       Infections/IMMUNOLOGY/MORTALITY/*PHYSIOPATHOLOGY  HIV Seronegativity
       HIV Seropositivity/IMMUNOLOGY  Recurrence  Time Factors  Tuberculosis,
       Pulmonary/MORTALITY/*PHYSIOPATHOLOGY  T4 Lymphocytes  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).